Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,639 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Functional Medicine Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

NCT05203965
View directory record Official record
Conditions
Familial Alcoholism Vulnerability
Interventions
Mavoglurant (AFQ056), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Not listed Not applicable Interventional

Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy

NCT04120077
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
EyePromise DVS, EyePromise DVS plus EyePromise EZTears
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial

NCT01919411
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 3 Interventional

Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients

NCT00137345
View directory record Official record
Conditions
Kidney Transplant
Interventions
sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
13 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 14, 2026, 8:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

NCT04640077
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
Interventions
No Intervention, donanemab
Other · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
23
States / cities
Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder

NCT06695767
View directory record Official record
Conditions
Major Depressive Disorder, Epilepsy
Interventions
Neurobehavioral therapy
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT04953897
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

NCT00940589
View directory record Official record
Conditions
Alzheimer's Disease, Sleep Disorder
Interventions
Circadin, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Brooksville, Florida • St. Petersburg, Florida • Mount Arlington, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Pilot Study of Adjunctive Yoga for Bipolar Depression

NCT02402010
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Adjunctive Yoga, Enhanced Treatment as Usual
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 14, 2026, 8:59 AM EDT
Not listed Phase 3 Interventional

Enhancing Rehabilitation After Stroke

NCT00868010
View directory record Official record
Conditions
Ischemic Stroke
Interventions
donepezil, placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Warren, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 1 Interventional Results available

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

NCT00585546
View directory record Official record
Conditions
Heart Failure, Dilated Cardiomyopathy
Interventions
clenbuterol
Drug
Lead sponsor
Francis D. Pagani
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Experimental Sleep Disturbances on Receptor Function of Study Drug

NCT04299490
View directory record Official record
Conditions
Sleep Disorder, Healthy
Interventions
Sleep Fragmentation, Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo), Sleep Continuity Disruption, Undisturbed Sleep
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting Phase 2 Interventional

Pilot fMRI Studies of Aging-Related Effects of THC

NCT06647524
View directory record Official record
Conditions
THC
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 14, 2026, 8:59 AM EDT
Suspended Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes

NCT02785120
View directory record Official record
Conditions
Ischemic Stroke
Interventions
TF0023
Drug
Lead sponsor
Techfields Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
24
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Englewood, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Mental Health and School Performance in Urban Eighth Graders

NCT03906682
View directory record Official record
Conditions
Depressive Symptoms, Trauma, Psychological, Disruptive Behavior
Interventions
RAP Club, Healthy Topics
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cancer Family Caregivers' Knowledge and Communication About Care Options

NCT02616107
View directory record Official record
Conditions
Family Caregivers
Interventions
Managing Cancer Care: A Caregiver's Guide, Symptom Management Toolkit
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 110 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

NCT01056107
View directory record Official record
Conditions
Irritable Bowel Syndrome Constipation Predominant
Interventions
ROSE-010, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

NCT02581592
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 14, 2026, 8:59 AM EDT